Transaction DateRecipientSharesTypePriceValue
27th August 2020Jean Francois Formela10,097Open or private sale$14.38$145,217.07
26th August 2020Jean Francois Formela44,381Open or private sale$14.80$656,745.60
25th August 2020Jean Francois Formela34,410Open or private sale$15.00$516,160.32
23rd July 2020Group Llc/Ma Baupost2,556,891Open or private purchase$39.11$100,000,007.01
30th June 2020Human Genetic Therapies, Inc. Shire6,824,992Open or private sale$20.68$141,140,834.56
26th June 2020Group Llc/Ma Baupost500,000Open or private purchase$22.00$11,000,000.00
3rd June 2020Human Genetic Therapies, Inc. Shire40,086Open or private sale$19.75$791,698.50
2nd June 2020Human Genetic Therapies, Inc. Shire100,389Open or private sale$19.75$1,982,682.75
2nd June 2020Human Genetic Therapies, Inc. Shire5,006Open or private sale$20.02$100,220.12
1st June 2020Human Genetic Therapies, Inc. Shire107,072Open or private sale$19.85$2,125,379.20
Translate Bio
Translate Bio logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.



Ticker: TBIO
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1693415
Employees:
Exchange:
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $272 M (0%)
Assets, Current: $316 M (55%)
Property, Plant and Equipment, Net: $15 M (0%)
Other Assets, Noncurrent: $10 M (268%)
Assets: $454 M (35%)
Accounts Payable, Current: $13 M (-19%)
Accrued Liabilities, Current: $11 M (0%)
Liabilities, Current: $52 M (24%)
Liabilities: $183 M (0%)
Common Stock, Value, Issued: $69 Th (15%)
Common Stock, Shares, Issued: $69 M (15%)
Retained Earnings (Accumulated Deficit): $410 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $540 Th (-27%)
Stockholders' Equity (Parent): $271 M (0%)
Liabilities and Equity: $454 M (35%)
Revenue: $16 M (0%)
Research and Development: $29 M (-42%)
General and Administrative Expenses: $9 M (-46%)
Operating Income/Loss: $37 M (-28%)